INFLAMASE FORTE Rx
Generic Name and Formulations:
Prednisolone sodium phosphate 1%; oph soln; contains benzalkonium chloride.
Indications for INFLAMASE FORTE:
Initially 1–2 drops every hour during day and every 2 hours at night; after response, reduce to 1 drop every 4 hours; then 1 drop 3–4 times daily as needed.
Ocular fungal, mycobacterial, viral (except herpes zoster), or untreated bacterial infections.
Not for use after uncomplicated removal of foreign body. Corneal or scleral thinning. Glaucoma. Monitor IOP and for secondary infections. Avoid abrupt cessation in prolonged use. Pregnancy (Cat.C). Nursing mothers.
Prolonged use: increased IOP, cataracts, corneal perforations, optic nerve damage, delayed wound healing; may mask or worsen infections.
Soln—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities